Previous 10 | Next 10 |
2024-01-16 13:12:52 ET Summary RxSight reported preliminary Q4 results, capping off a record year for growth where sales climbed by approximately 82%. The company is capturing strong demand for its adjustable intraocular lens technology for cataract and lens replacement surgery. ...
2024-01-11 18:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 11:40:19 ET More on STAAR Surgical STAAR Surgical: Slowly Coming In My Sight STAAR Surgical Q3 2023 Earnings Call Transcript STAAR Surgical: Not In My Sight Yet STAAR Surgical Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on ...
Net Sales Up 19% for Fourth Quarter and 13% for Fiscal 2023 1 ICL Sales Up 22% for Fourth Quarter and 18% for Fiscal 2023 Provides Fiscal 2024 Sales Outlook of $335 Million to $340 Million STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and m...
2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...
2023-12-27 11:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-26 10:11:30 ET Summary STAAR Surgical Company offers the EVO ICL Lens, a clear vision solution for nearsightedness without the need for contact lenses or glasses. The company has seen steady growth in its operations and market share in the vision correction category. D...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023. ...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced that management will participate in the Stephens Annual Investment Conference on Thursday, Nov...
2023-11-02 10:01:01 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial resu...
EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ: K), a leading developer, manufactu...
Agreement is Largest Commitment to EVO ICL™ in the U.S. STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announces another m...